We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This review article is a summary of recommendations from experts in the field of diabetes and endocrinology regarding the relationship between diabetes and the coronavirus disease 2019 (COVID-19). Furthermore, the authors offer practical management recommendations for this patient population and discuss the needs of specific diabetic patient groups. According to the authors, 20% to 50% of COVID-19 patients globally had diabetes. Healthcare practitioners should understand the impact of COVID-19 on diabetes management, such as considerations for the use of diabetic drug therapy in patients who are positive for COVID-19.
The impact of COVID-19 on diabetic patient groups has yet to fully understood. More clinical trials are needed to understand whether the recommendations provided by the authors will be practical for managing diabetes in the context of COVID-19.
-Ana Perdigoto, MD
This abstract is available on the publisher's site.
Diabetes is one of the most important comorbidities linked to the severity of all three known human pathogenic coronavirus infections, including severe acute respiratory syndrome coronavirus 2. Patients with diabetes have an increased risk of severe complications including Adult Respiratory Distress Syndrome and multi-organ failure. Depending on the global region, 20-50% of patients in the coronavirus disease 2019 (COVID-19) pandemic had diabetes. Given the importance of the link between COVID-19 and diabetes, we have formed an international panel of experts in the field of diabetes and endocrinology to provide some guidance and practical recommendations for the management of diabetes during the pandemic. We aim to briefly provide insight into potential mechanistic links between the novel coronavirus infection and diabetes, present practical management recommendations, and elaborate on the differential needs of several patient groups.
Practical Recommendations for the Management of Diabetes in Patients With COVID-19
Lancet Diabetes Endocrinol 2020 Apr 23;[EPub Ahead of Print], SR Bornstein, F Rubino, K Khunti, G Mingrone, D Hopkins, AL Birkenfeld, B Boehm, S Amiel, RI Holt, JS Skyler, JH DeVries, E Renard, RH Eckel, P Zimmet, KG Alberti, J Vidal, B Geloneze, JC Chan, L Ji, B Ludwig